Citations

Mayo Clinic

Showing 10 of 108572 citations.

Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Zhang, Ting , Ambrodji, Alisa , Huang, Huixing, Bouchonville, Kelly J. , Etheridge, Amy S. , Schmidt, Remington E. , Bembenek, Brianna M. , Temesgen, Zoey B., Wang, Zhiquan , Innocenti, Federico , Diasio, Robert B. , Temesgen, Zoey B , Stroka, Deborah , Largiadèr, Carlo R , Offer, Steven M , Largiadèr, Carlo R. , Offer, Steven M. , Wang, Zhiquan

eLife | January 10, 2024 | Volume: 13 | Issue: No issue available | Pages: No page available

10.7554/elife.94075 | PMID 38686795 Get It

Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the precise mechanisms remain elusive. Using a well-defined drug-gene pair, we identified an enhancer region for dihydropyrimidine dehydrogenase (DPD, DPYD gene) expression that is relevant to the metabolism of the anti-cancer drug 5-fluorouracil (5-FU). Using reporter systems, CRISPR genome-edited cell models, and human liver specimens, we demonstrated in vitro and vivo that genotype status for the common germline variant (rs4294451; 27% global minor allele frequency) located within this novel enhancer controls DPYD transcription and alters resistance to 5-FU. The variant genotype increases recruitment of the transcription factor CEBPB to the enhancer and alters the level of direct interactions between the enhancer and DPYD promoter. Our data provide insight into the regulatory mechanisms controlling sensitivity and resistance to 5-FU.
MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: Yes
Contentti, Edgar Carnero , Wingerchuk, Dean M. , Carnero Contentti, Edgar

Multiple Sclerosis Journal | January 10, 2024 | Volume: 30 | Issue: 1 | Pages: 19-21

10.1177/13524585231222132 | PMID 38197556 Get It

Ultrasonic- and Ultrasound-assisted Improvement of Silhouette of the Torso: Bone Structure High-definition Remodeling (Part I)
Valdivieso, Carlos Oñate, Valdivieso, Daniel Oñate, Villa, Hugo Aguilar , Michels, Paulo Jr Alberton, Viera, Andres, Benavides, Jorge E., Flórez, Silvia Juliana Villabona , Ramírez, Brian , Perez Pachon, Mauricio E, Hoyos, Alfredo E. , Perez, Mauricio E.

Plastic and Reconstructive Surgery - Global Open | January 10, 2024 | Volume: 12 | Issue: 1 | Pages: e5513

10.1097/gox.0000000000005513 | PMID 38204869 Get It

Background: High-definition liposculpture allowed plastic surgeons to achieve better aesthetic results by carving the underlying muscles and contours in a new way. Several authors have improved the original technique by adding other procedures and new technologies. We designed a new improvement by incorporating bone transformation surgery to overcome the lack of silhouette at the waist and, as a result, optimize the breast-waist-hip ratios. Methods: We carried out a prospective multicenter study, with five different surgeons performing the same rib remodeling technique for waist definition. We used an ultrasonic piece for costal corticotomy and real-time ultrasound imaging to perform green-stick fractures over the last two or three floating ribs. Ours is a new technique based on the prior one described by Kudzaev. Results: We reported 131 consecutive patients who were enrolled in this study. Waistline diameter decreased an average of 8 cm after surgery ( P < 0.05). Most patients were women (n = 125, 95.4%). No major complications were reported. Most common complication was prolonged pain, with only three cases of contour asymmetry, all of which were attributable to noncompliance of constantly wearing the corset + compressive garments. Patients reported a high satisfaction rate and fast recovery (Body-QoL survey). Conclusions: Ultrasonic- and ultrasound- assisted indentation surgery of the thorax is a safe and reliable technique for waistline definition, with a high satisfaction rate, almost-invisible scars, and minimal risk for complications. Incorporation of high-definition liposculpture to rib remodeling opens up a new horizon for bone structure modification surgery (S-high-definition remodeling) that can be safely performed for patients who seek better aesthetic outcomes in body contouring.
Beating heart transapical septal myectomy—a less invasive septal reduction option for hypertrophic cardiomyopathy
Quintana, Eduard , Mestres, Carlos A. , Mestres, Carlos A , Schaff, Hartzell V. , Stradiņš, Pēteris

European Journal of Cardio-Thoracic Surgery | January 10, 2024 | Volume: 65 | Issue: 1 | Pages: No page available

10.1093/ejcts/ezae003 | PMID 38195900 Get It

Staging of breast cancer in the breast and regional lymph nodes using contrast-enhanced photon-counting detector CT: accuracy and potential impact on patient management
Yalon, Mariana , Sae-Kho, Tiffany, Khanna, Akriti , Chang, Shaojie , Andrist, Boleyn R., Weber, Nikkole M. , Hoodeshenas, Safa , Ferrero, Andrea , Glazebrook, Katrina N. , Baffour, Francis I , Sae-Kho, Tiffany M. , McCollough, Cynthia H. , Baffour, Francis

British Journal of Radiology | January 10, 2024 | Volume: 97 | Issue: 1153 | Pages: 93-97

10.1093/bjr/tqad042 | PMID 38263843 Get It

Abstract Objectives To describe the feasibility and evaluate the performance of multiphasic photon-counting detector (PCD) CT for detecting breast cancer and nodal metastases with correlative dynamic breast MRI and digital mammography as the reference standard. Methods Adult females with biopsy-proven breast cancer undergoing staging breast MRI were prospectively recruited to undergo a multiphasic PCD-CT using a 3-phase protocol: a non-contrast ultra-high-resolution (UHR) scan and 2 intravenous contrast-enhanced scans with 50 and 180 s delay. Three breast radiologists compared CT characteristics of the index malignancy, regional lymphadenopathy, and extramammary findings to MRI. Results Thirteen patients underwent both an MRI and PCD-CT (mean age: 53 years, range: 36-75 years). Eleven of thirteen cases demonstrated suspicious mass or non-mass enhancement on PCD-CT when compared to MRI. All cases with metastatic lymphadenopathy (3/3 cases) demonstrated early avid enhancement similar to the index malignancy. All cases with multifocal or multicentric disease on MRI were also identified on PCD-CT (3/3 cases), including a 4 mm suspicious satellite lesion. Four of five patients with residual suspicious post-biopsy calcifications on mammograms were detected on the UHR PCD-CT scan. Owing to increased field-of-view at PCD-CT, a 5 mm thoracic vertebral metastasis was identified at PCD-CT and not with the breast MRI. Conclusions A 3-phase PCD-CT scan protocol shows initial promising results in characterizing breast cancer and regional lymphadenopathy similar to MRI and detects microcalcifications in 80% of cases. Advances in knowledge UHR and spectral capabilities of PCD-CT may allow for comprehensive characterization of breast cancer and may represent an alternative to breast MRI in select cases.
Implantable cardioverter defibrillator use in arrhythmogenic right ventricular cardiomyopathy in North America and Europe
Carrick, Richard , Marco, Corrado De , Gasperetti, Alessio , Bosman, Laurens P. , Trancuccio, Alessandro , Mazzanti, Andrea , Murray, Brittney , Pendleton, Catherine, Tichnell, Crystal , Tandri, Harikrishna , Zeppenfeld, Katja , Wilde, Arthur A.M. , Davies, Brianna , Seifer, Colette , Roberts, Jason D. , MacIntyre, Ciorsti, Alqarawi, Wael , Cutler, Michael J. , Targetti, Mattia , Calò, Leonardo , Vitali, Francesco , Compagnucci, Paolo , Cappelletto, Chiara, Duru, Fırat , Jensen, Henrik Kjærulf , Svensson, Anneli , Dahlberg, Pia , Hasselberg, Nina E. , Marco, Andrea Di , Jordà, Paloma , Weidmann, Zoraida Moreno , Borowiec, Karolina , Delinière, Antoine , Tintelen, J. Peter van , Olivotto, Iacopo , Saguner, Ardan M. , Cox, Moniek G.P.J. , Merlo, Marco , Riele, Anneline S.J.M. te , Wu, Kathérine C. , Calkins, Hugh , James, Cynthia A. , Cadrin‐Tourigny, Julia , Carrick, Richard T , De Marco, Corrado , Gourraud, Jean-Baptiste , Trancuccio, Alessandro , Mazzanti, Andrea , Murray, Brittney , Zeppenfeld, Katja , Davies, Brianna , Alqarawi, Wael , Bertini, Matteo , Compagnucci, Paolo , Cappelletto, Chiara , Stolfo, Davide , Duru, Firat , Di Marco, Andrea , Arbelo, Elena , Delinière, Antoine , Saguner, Ardan M , Merlo, Marco , Krahn, Andrew D , Te Riele, Anneline S J M , Calkins, Hugh , James, Cynthia A , Cadrin-Tourigny, Julia , van Tintelen, J Peter , Olivotto, Iacopo , Jensen, Henrik Kjærulf , Gourraud, Jean‐Baptiste , Healey, Jeff S. , Tadros, Rafik , Casella, Michela , Russo, Antonio Dello , Luca, Antonio De , Arbelo, Elena , Biernacka, Elżbieta Katarzyna , Platonov, Pyotr G. , Haugaa, Kristina H. , Tondo, Claudio , Krahn, Andrew D.

European Heart Journal | January 10, 2024 | Volume: 45 | Issue: 7 | Pages: 538-548

10.1093/eurheartj/ehad799 | PMID 38195003 Get It

Abstract Background and Aims Implantable cardioverter-defibrillators (ICDs) are critical for preventing sudden cardiac death (SCD) in arrhythmogenic right ventricular cardiomyopathy (ARVC). This study aims to identify cross-continental differences in utilization of primary prevention ICDs and survival free from sustained ventricular arrhythmia (VA) in ARVC. Methods This was a retrospective analysis of ARVC patients without prior VA enrolled in clinical registries from 11 countries throughout Europe and North America. Patients were classified according to whether they received treatment in North America or Europe and were further stratified by baseline predicted VA risk into low- (&lt;10%/5 years), intermediate- (10%–25%/5 years), and high-risk (&gt;25%/5 years) groups. Differences in ICD implantation and survival free from sustained VA events (including appropriate ICD therapy) were assessed. Results One thousand ninety-eight patients were followed for a median of 5.1 years; 554 (50.5%) received a primary prevention ICD, and 286 (26.0%) experienced a first VA event. After adjusting for baseline risk factors, North Americans were more than three times as likely to receive ICDs {hazard ratio (HR) 3.1 [95% confidence interval (CI) 2.5, 3.8]} but had only mildly increased risk for incident sustained VA [HR 1.4 (95% CI 1.1, 1.8)]. North Americans without ICDs were at higher risk for incident sustained VA [HR 2.1 (95% CI 1.3, 3.4)] than Europeans. Conclusions North American ARVC patients were substantially more likely than Europeans to receive primary prevention ICDs across all arrhythmic risk strata. A lower rate of ICD implantation in Europe was not associated with a higher rate of VA events in those without ICDs.
Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature
Abdelbaky, Salma , Giacopelli, Brian , Rabe, Kari G. , Yamaguchi, Kyoko , Wu, Yue-Zhong, Yan, Huihuang , Shanafelt, Tait D. , Parikh, Sameer A. , Hampel, Paul J. , Brown, Sochilt , Vachon, Celine M. , Hanson, Curtis A. , Parker, Alexander S. , Oakes, Christopher C. , Ding, Wei , Hampel, Paul J , Cerhan, James R , Vachon, Celine M. , Kay, Neil E , Braggio, Esteban , Slager, Susan L , Oakes, Christopher C , Chaffee, Kari G. , Ding, Wei , Parikh, Sameer A , Shanafelt, Tait D , Ding, Wei , Cerhan, James R. , Kay, Neil E. , Braggio, Esteban , Slager, Susan L.

Blood | January 9, 2024 | Volume: 143 | Issue: 17 | Pages: 1752-1757

10.1182/blood.2023022180 | PMID 38194687 Get It

Abstract Monoclonal B-cell lymphocytosis (MBL) progresses to chronic lymphocytic leukemia (CLL) requiring therapy at 1% to 5% per year. Improved prediction of progression would greatly benefit individuals with MBL. Patients with CLL separate into 3 distinct epigenetic subtypes (epitypes) with high prognostic significance, and recently the intermediate epitype has been shown to be enriched for high-risk immunoglobulin lambda variable (IGLV) 3-21 rearrangements, impacting outcomes for these patients. Here, we employed this combined strategy to generate the epigenetic and light chain immunoglobulin (ELCLV3-21) signature to classify 219 individuals with MBL. The ELCLV3-21 high-risk signature distinguished MBL individuals with a high probability of progression (39.9% and 71.1% at 5 and 10 years, respectively). ELCLV3-21 improved the accuracy of predicting time to therapy for individuals with MBL compared with other established prognostic indicators, including the CLL international prognostic index (c-statistic, 0.767 vs 0.668, respectively). Comparing ELCLV3-21 risk groups in MBL vs a cohort of 226 patients with CLL revealed ELCLV3-21 high-risk individuals with MBL had significantly shorter time to therapy (P = .003) and reduced overall survival (P = .03) compared with ELCLV3-21 low-risk individuals with CLL. These results highlight the power of the ELCLV3-21 approach to identify individuals with a higher likelihood of adverse clinical outcome and may provide a more accurate approach to classify individuals with small B-cell clones.
Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low–Tumor Burden Follicular Lymphoma
Kahl, Brad S. , Jegede, Opeyemi A. , Peterson, Christopher G., Swinnen, Lode J., Weiss, Matthias , Fishkin, Paul A. S., Fenske, Timothy S. , Williams, Michael E. , Weiss, Matthias , Fenske, Timothy S , Williams, Michael E , Jagede, Opeyemi A. , Kahl, Brad S , Peterson, Christopher, Habermann, Thomas M. , Schuster, Stephen J.

Journal of Clinical Oncology | January 9, 2024 | Volume: 42 | Issue: 7 | Pages: 774-778

10.1200/jco.23.01912 | PMID 38194625 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. In 2003, the Eastern Cooperative Oncology Group initiated a randomized phase III clinical trial (E4402) comparing two different rituximab dosing strategies for patients with previously untreated low–tumor burden follicular lymphoma. Rituximab-responsive patients (n = 299) were randomly assigned to either a retreatment rituximab (RR) strategy or a maintenance rituximab (MR) strategy. Each dosing strategy was continued until treatment failure. The primary end point of the study was time to treatment failure (TTF). In the original report, there was no difference in TTF between the two dosing strategies. Here, we report on the long-term outcomes for secondary end points of time to first cytotoxic therapy, duration of response, and overall survival (OS). At 7 years, 83% of MR patients had not required first chemotherapy compared with 63% of RR patients (hazard ratio, 2.37 [95% CI, 1.5 to 3.76]). At 7 years, 71% of MR remained in their first remission compared with 37% of RR patients. Despite the improved first remission length with MR, there was no difference in OS at 10 years (83% v 84%). With mature long-term data, we confirm that prolonged maintenance rituximab does not confer an OS advantage in low–tumor burden follicular lymphoma.
Feasibility of using a transmission ion chamber for QA tests of medical linear accelerators
Farrokhkish, Makan, Veres, Andrew J., Santos, Luis E. Fong de los, DeMarco, John J., Islam, Mohammad K. , Fong de Los Santos, Luis E

Journal of Applied Clinical Medical Physics | January 9, 2024 | Volume: 25 | Issue: 2 | Pages: No page available

10.1002/acm2.14245 | PMID 38194595 Get It

AbstractPurposeTo study the feasibility of using the Integral Quality Monitoring (IQM) system for routine quality assurance (QA) of photon beams.MethodsThe IQM system is a commercially available dose delivery verification tool, which consists of a spatially sensitive large area transmission ion chamber, mounted on the Linac collimator, and a calculation algorithm to predict the signals in response to radiation beams. By comparing the measured and predicted signals the system verifies the accuracy of beam delivery. The ion chamber unit is a battery powered system including a dual‐electrometer, temperature and pressure sensors, and inclinometers. The feasibility of using the IQM system for routine QA tests was investigated by measuring constancy values of beam parameters, with specially designed tests fields, and comparing them with those determined by a conventional system.ResultsThe sensitivity of the beam output constancy measurements by the IQM system was found to agree with those measured by a Farmer type ion chamber placed in water phantoms to within 0.1% for typical daily output variation of ± 0.5% and ± 1%. The beam symmetry was measured with a 4 cm × 4 cm aperture at multiple off‐axis distances and was found to have a highly linear relationship with those measured in a water phantom scan for intentionally introduced asymmetry between ‐3% and +3%. The beam flatness was measured with a two‐field ratio method and was found to be linearly correlated with those measured by water phantom scan. The dosimetric equivalent of a picket fence test performed by the IQM system can serve as a constancy check of the multileaf collimator (MLC) bank positioning test.ConclusionsThe IQM system has been investigated for constancy measurements of various beam parameters for photon beams. The results suggest that the system can be used for most of the routine QA tests effectively and efficiently.
Robotic Resection of Presacral Tumors
Violante, Tommaso , Addison, Poppy , Perry, William , Merchea, Amit , Mathis, Kellie L. , Dozois, Eric J. , Violante, Tommaso , Perry, William R

No container title available | January 9, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3837760/v1 Get It

Abstract Background:Presacral tumors are a rare entity typically treated with an open surgical approach. A limited number of minimally invasive resections have been described. Aim of the study was to evaluate the safety and efficacy of robotic resection of presacral tumors. Methods: This was a retrospective single system analysis, conducted at a quaternary referral academic healthcare system, and included all patients who underwent a robotic excision of a presacral tumor between 2015 and 2023. Outcomes of interest were operative time, estimated blood loss, complications, length of stay, margin status, and recurrence rates. Results: Sixteen patients (11 females, 5 males) were included. Median age of the cohort was 51 years (range 25-69). Median operative time was 197 minutes (range 98-802). Median estimated blood loss was 40 ml, ranging from 0 to 1800 ml, with one patient experiencing conversion to open surgery after uncontrolled hemorrhage. Urinary retention was the only post-operative complication that occurred in 3 patients (19%) and was solved within 30 days in all cases. Median length of stay was one day (range 1-6). Median follow-up was 6.7 months (range 1-110). All tumors were excised with appropriate margins, but one benign and one malignant tumor recurred (12.5%). Ten tumors were classified as congenital (one was malignant), two were mesenchymal (both malignant), and five were miscellaneous (one malignant). Conclusions:Robotic resection of select presacral pathology is feasible and safe. Further studies must be conducted to determine complication rates, outcomes, and long-term safety profiles.